Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been assigned an average recommendation of “Buy” from the fourteen research firms that are currently covering the stock. Two investment analysts have rated the stock with a sell rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $15.81.
Several equities analysts have recently issued reports on KPTI shares. Vetr cut shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating and set a $11.00 price objective on the stock. in a research note on Wednesday, August 31st. S&P Equity Research dropped their target price on shares of Karyopharm Therapeutics from $9.06 to $7.55 in a research report on Tuesday, August 30th. Leerink Swann reissued an “outperform” rating and issued a $18.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, October 7th. Jefferies Group raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and lifted their target price for the stock from $9.00 to $12.00 in a research report on Tuesday, August 30th. Finally, Wedbush reissued an “outperform” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, August 4th.
Hedge funds have recently bought and sold shares of the stock. Metropolitan Life Insurance Co. NY acquired a new stake in Karyopharm Therapeutics during the second quarter worth about $136,000. Nationwide Fund Advisors boosted its stake in Karyopharm Therapeutics by 38.3% in the second quarter. Nationwide Fund Advisors now owns 21,258 shares of the company’s stock worth $143,000 after buying an additional 5,886 shares during the period. ProShare Advisors LLC boosted its stake in Karyopharm Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 29,655 shares of the company’s stock worth $199,000 after buying an additional 376 shares during the period. Highbridge Capital Management LLC acquired a new stake in Karyopharm Therapeutics during the second quarter worth about $200,000. Finally, Alliancebernstein L.P. boosted its stake in Karyopharm Therapeutics by 24.2% in the second quarter. Alliancebernstein L.P. now owns 34,930 shares of the company’s stock worth $234,000 after buying an additional 6,800 shares during the period. Hedge funds and other institutional investors own 55.68% of the company’s stock.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) opened at 8.61 on Wednesday. The stock has a 50 day moving average of $9.32 and a 200 day moving average of $8.43. Karyopharm Therapeutics has a 52-week low of $4.83 and a 52-week high of $19.41. The firm’s market cap is $309.87 million.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.08. Equities analysts predict that Karyopharm Therapeutics will post ($3.22) EPS for the current fiscal year.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.